Showing results (71-80 of 92) with videos related to
Sort By:
Pageof 10
Journal of Gastroenterology|November 19, 2020
Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infectionKazuharu Suzuki, Goki Suda, Yoshiya Yamamoto, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 20, 2017
Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled studyGoki Suda, Jun Ito, Atsushi Nagasaka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 12, 2014
Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactionsGoki Suda, Yoshiya Yamamoto, Astushi Nagasaka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 25, 2024
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective studyZijian Yang, Goki Suda, Takuya Sho, et al.Journal of Gastroenterology|January 16, 2016
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis CGoki Suda, Mineo Kudo, Atsushi Nagasaka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 13, 2016
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairmentGoki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2018
Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunctionTakuya Sho, Goki Suda, Atsushi Nagasaka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2020
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.Journal of Clinical Pathology|December 17, 2015
ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinomaKatsumi Terashita, Makoto Chuma, Yutaka Hatanaka, et al.JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 15, 2020
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world settingTakuya Sho, Goki Suda, Koji Ogawa, et al.Pageof 10